[go: up one dir, main page]

WO2003000021A3 - Acides nucleiques et polypeptides pancam - Google Patents

Acides nucleiques et polypeptides pancam Download PDF

Info

Publication number
WO2003000021A3
WO2003000021A3 PCT/US2002/020275 US0220275W WO03000021A3 WO 2003000021 A3 WO2003000021 A3 WO 2003000021A3 US 0220275 W US0220275 W US 0220275W WO 03000021 A3 WO03000021 A3 WO 03000021A3
Authority
WO
WIPO (PCT)
Prior art keywords
pancam
polypeptides
named
nucleic acids
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/020275
Other languages
English (en)
Other versions
WO2003000021A2 (fr
Inventor
Chao Sun
John P Carulli
Alexander V Lukashin
Daniel R Kilburn
Humphrey Athelstan Roy Gardner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/019904 external-priority patent/WO2001098360A2/fr
Application filed by Biogen Inc filed Critical Biogen Inc
Priority to CA002451271A priority Critical patent/CA2451271A1/fr
Priority to NZ530696A priority patent/NZ530696A/en
Priority to EP02756316A priority patent/EP1409523A4/fr
Priority to JP2003506477A priority patent/JP4224395B2/ja
Priority to AU2002322331A priority patent/AU2002322331B2/en
Priority to CA002459985A priority patent/CA2459985A1/fr
Publication of WO2003000021A2 publication Critical patent/WO2003000021A2/fr
Publication of WO2003000021A3 publication Critical patent/WO2003000021A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un polynucléotide isolé codant pour un nouveau membre de la superfamille des immunoglobulines appelé PanCAM (également appelé GP354). PanCAM comprend un domaine transmembranaire unique prédit et cinq domaines de type immunoglobuline (Ig) dans la partie extracellulaire de la protéine. La structure protéique et la répartition tissulaire de PanCAM indiquent que cette dernière joue un rôle dans les événements de reconnaissance, de liaison, de signalisation et d'adhérence entre cellules, dans le pancréas (en particulier dans les îlots bêta), l'hypophyse, et le système nerveux central (SNC). L'invention concerne également des polynucléotides et des polypeptides isolés apparentés à PanCAM, des vecteurs et des cellules hôtes comprenant l'un de ceux-ci, des anticorps dirigés contre PanCAM, des cellules produisant de tels anticorps, et des méthodes diagnostiques et thérapeutiques connexes.
PCT/US2002/020275 2001-06-22 2002-06-24 Acides nucleiques et polypeptides pancam Ceased WO2003000021A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002451271A CA2451271A1 (fr) 2001-06-22 2002-06-24 Acides nucleiques et polypeptides pancam
NZ530696A NZ530696A (en) 2001-06-22 2002-06-24 Pancam nucleic acids and polypeptides
EP02756316A EP1409523A4 (fr) 2001-06-22 2002-06-24 Acides nucleiques et polypeptides pancam
JP2003506477A JP4224395B2 (ja) 2001-06-22 2002-06-24 ＰａｎＣＡＭ核酸およびポリペプチド
AU2002322331A AU2002322331B2 (en) 2001-06-22 2002-06-24 Pancam nucleic acids and polypeptides
CA002459985A CA2459985A1 (fr) 2001-06-22 2002-06-24 Acides nucleiques et polypeptides pancam

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2001/019904 WO2001098360A2 (fr) 2000-06-22 2001-06-22 Acides nucleiques et polypeptides de gp354
USPCT/US01/19904 2001-06-22

Publications (2)

Publication Number Publication Date
WO2003000021A2 WO2003000021A2 (fr) 2003-01-03
WO2003000021A3 true WO2003000021A3 (fr) 2003-11-20

Family

ID=21742663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/020275 Ceased WO2003000021A2 (fr) 2001-06-22 2002-06-24 Acides nucleiques et polypeptides pancam

Country Status (5)

Country Link
EP (1) EP1409523A4 (fr)
JP (1) JP4224395B2 (fr)
AU (1) AU2002322331B2 (fr)
CA (2) CA2459985A1 (fr)
WO (1) WO2003000021A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650380A1 (fr) 2006-04-28 2007-11-08 Oregon Health & Science University Anticorps monoclonaux et leur utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068848A2 (fr) * 2000-03-01 2001-09-20 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005509B1 (en) * 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
JPH11507845A (ja) * 1997-02-13 1999-07-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経細胞付着分子スプライシング変種

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068848A2 (fr) * 2000-03-01 2001-09-20 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Also Published As

Publication number Publication date
EP1409523A2 (fr) 2004-04-21
CA2459985A1 (fr) 2003-01-03
JP2005508147A (ja) 2005-03-31
WO2003000021A2 (fr) 2003-01-03
EP1409523A4 (fr) 2005-06-15
JP4224395B2 (ja) 2009-02-12
CA2451271A1 (fr) 2003-01-03
AU2002322331B2 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
CA2285040A1 (fr) Recepteur 5 contenant un domaine de mort
WO1998030693A3 (fr) Recepteur 5 du facteur de necrose tumorale
PT842273E (pt) Ligando de receptor vegf-c
DE69840966D1 (de) Homolog NL6 des Tie Rezeptor Tyrosinekinase Liganden
WO1999055868A3 (fr) Proteines fizz
WO1997033995A3 (fr) Molecules de signalisation de matrice extracellulaire
WO2001055308A3 (fr) Acides nucleiques, proteines et anticorps
WO2001088092A3 (fr) Procedes et materiaux relatifs aux polypeptides et polynucleotides du type facteur des cellules souches (du type fcs)
ATE371727T1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
WO2001053454A3 (fr) Procedes et elements ayant trait a des polypeptides et des polynucleotides de type recepteurs couples a une proteine g
WO2000000515A3 (fr) RECEPTEUR DE CHEMOKINES OBTENU A PARTIR D'UNE BIBLIOTHEQUE D'ADNc DE FOIE-RATE DE FOETUS
WO2000066156A8 (fr) Recepteur 5 contenant le domaine de l'apoptose
WO2004043403A3 (fr) Polypeptides synthetiques a domaine unique imitant l'apolipoproteine e et methodes d'utilisation
WO2001098360A3 (fr) Acides nucleiques et polypeptides de gp354
WO2000067793A8 (fr) Recepteur 4 contenant le domaine de la mort cellulaire programmee
WO2003000021A3 (fr) Acides nucleiques et polypeptides pancam
WO1999025832A8 (fr) Proteine toso
DK0968288T3 (da) z219a, en human homolog til 2-19 protein
WO1996023884A3 (fr) Recepteurs humains actives par les proliferateurs du peroxisome
WO2000059942A3 (fr) COMPOSITIONS hOB-BP2h, LEURS TECHNIQUES ET LEURS UTILISATIONS
WO2002000727A3 (fr) Polypeptides et acides nucleiques gp286
WO1998027932A3 (fr) Proteine specifique du cervelet et de l'embryon
WO2004090103A3 (fr) Identification de nouveaux nogo-recepteurs et procedes associes
WO1998031810A3 (fr) Chemokines de mammiferes, recepteurs, reactifs, utilisations
WO2001032871A3 (fr) Proteine zfsta4 de type follistatine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003506477

Country of ref document: JP

Ref document number: 2459985

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002322331

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002756316

Country of ref document: EP

Ref document number: 530696

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2002756316

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2002322331

Country of ref document: AU

Date of ref document: 20020624

Kind code of ref document: B